Iain Lachlan Mclean MD, PhD, MBChB

Lachy McLean, MBChB, Ph.D., as Chief Medical Officer. An experienced biopharmaceutical executive, Dr. McLean brings to Novome significant clinical drug development and translational medicine experience.

Dr. McLean, a board-certified Rheumatologist, has been involved in developing innovative medicines from nonclinical research through to late-stage drug development, most recently as Head of Research at Traverse Therapeutics (formerly Retrophin). Prior to Traverse, for more than a decade, Dr. McLean held positions of increasing responsibility at Takeda Pharmaceuticals including Vice President and Global Head of Translational Clinical Science Immunology where he oversaw research and development programs for many early- to mid-stage molecules. Prior to Takeda, Dr. McLean was a Medical Director at Genentech where he was the clinical team leader for several immunology programs. He also held Director-level clinical research positions at Merck and AstraZeneca. Prior to industry, Dr. McLean was a Rheumatologist and Investigator at the University of Auckland.

“Lachy brings a wealth of experience to the Novome team, particularly in his breadth of experience across early- to late-stage clinical research and drug development in therapeutic areas highly-relevant to Novome’s GEMMs platform and pipeline,” said Blake Wise, Chief Executive Officer of Novome Biotechnologies. “Lachy is uniquely suited to join Novome as we transition to a clinical-stage company—I have no doubt that he will play a critical role in guiding and executing our lead clinical development candidate for the treatment of enteric hyperoxaluria and advancing other preclinical programs across our pipeline of GEMMs candidates, including in ulcerative colitis and irritable bowel syndrome.”

Dr. McLean earned a BMedSci and an MBChB (equivalent to an MD) from the University of Otago in New Zealand. He earned a Ph.D. in Immunology from the University of London. His education also includes a fellowship in rheumatology at the University of Texas Southwestern Medical Center at Dallas. Dr. McLean is a Fellow of the Royal College of Physicians (FRCP) and the Faculty of Pharmaceutical Medicine (FFPM) in the United Kingdom and of the Royal Australasian College of Physicians (FRACP). Dr. McLean has contributed to the medical literature as the lead or co-author on over 50 peer-reviewed journal articles and book chapters.